Every material Form 8-K Indivior filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Indivior's 8-K says a special dividend declared by the board on September 16, 2026 triggered an increase in the conversion rate on its 0.625% Convertible Senior Notes due 2031, from 24.0033 to 30.9355 common shares per $1,000 principal, a conversion price of approximately $32.33 per share. The filing is signed by Supernus, Inc. (f/k/a Indivior Pharmaceuticals, Inc.), and it states that no bondholders converted their notes for common stock.
Special dividend declared by the board on September 16, 2026 triggered the adjustment.
Conversion rate per $1,000 principal increased from 24.0033 to 30.9355 common shares.
Implied conversion price is approximately $32.33 per share.
No bondholders converted their notes for common stock.
Indivior and Supernus Pharmaceuticals completed their merger on November 2, 2026, forming a combined central nervous system biopharmaceutical company operating as Supernus, Inc. Legacy Indivior stockholders own approximately 56.5% of the combined company, and former Supernus stockholders own about 43.5%. The combined entity entered into a $650 million senior secured term loan facility to help fund a $1.0 billion aggregate special cash dividend to Indivior stockholders.
The merger was completed on November 2, 2026, creating a combined company that will trade under the ticker symbol SUPN starting November 3, 2026.
The combined company entered into a $650 million senior secured term loan facility with Citibank, N.A. on November 2, 2026.
Legacy Indivior stockholders own approximately 56.5% and former Supernus stockholders own approximately 43.5% of the combined company on a fully diluted basis.
Jack Khattar serves as President and CEO, and Tony Kingsley serves as Board Chair of the combined company.
Indivior reported third-quarter 2026 results with total net revenue of $356 million, up 13% year over year, and GAAP net income of $137 million ($1.12 diluted EPS), compared with $42 million a year earlier. The company said it is on track for its previously communicated 2026 guidance as a standalone company, but that guidance will no longer apply if its merger with Supernus closes as expected on November 2, 2026.
Total SUBLOCADE net revenue was $267 million, up 22% year over year; U.S. SUBLOCADE net revenue rose 24% to $252 million.
Adjusted EBITDA was $211 million, up 76% from $120 million a year earlier; GAAP operating expenses fell 33% to $125 million.
Cash and investments totaled $332 million at September 30, 2026.
Merger with Supernus is expected to close November 2, 2026; the combined company is to trade as SUPN from November 3, 2026.
Indivior reported second-quarter 2026 total net revenue of $343 million, up 14% year over year, and GAAP net income of $122 million, compared with $18 million a year earlier, and raised its full-year 2026 guidance. The company also announced a definitive agreement for an all-stock merger of equals with Supernus Pharmaceuticals, which it expects to close in the fourth quarter, so shareholders face both the improved outlook and the pending deal's terms and risks.
Q2 2026 total net revenue was $343 million, up from $302 million; total SUBLOCADE net revenue was $253 million, up 21%.
GAAP net income was $122 million ($0.98 diluted EPS) versus $18 million ($0.14 diluted EPS) in Q2 2025.
Full-year 2026 adjusted EBITDA guidance was raised to $700 million to $740 million from $620 million to $660 million; net revenue guidance was raised to $1,295 million to $1,365 million from $1,215 million to $1,285 million.
In Q2 2026 the company repurchased 4,664,540 shares for $175 million; the Supernus merger is expected to close in the fourth quarter.
On August 1, 2026, Supernus Pharmaceuticals entered a merger agreement with Indivior Pharmaceuticals and Artemis Merger Sub Inc., under which Supernus merges into the Indivior subsidiary and Indivior is renamed Supernus, Inc. Supernus shareholders would receive 1.5401 Indivior shares for each share held, and completion depends on shareholder approvals, antitrust clearance and other customary conditions.
Each Supernus share converts into 1.5401 Indivior shares at the effective time, and Supernus equity awards are assumed or converted into Indivior awards.
Indivior shareholders are expected to own about 56.5% of the combined company and Supernus shareholders about 43.5%, on a fully diluted basis.
Indivior will declare a $1.0 billion special cash dividend before the effective time, payable after the merger, backed by a $650 million senior secured term loan commitment from Citibank, N.A.
Either party may terminate if the merger is not effective within six months, extendable to twelve months; Indivior would pay a $174.0 million termination fee in certain cases and Supernus would pay $101.0 million in certain cases.
Indivior will eliminate its Chief Scientific Officer position effective June 1, 2026. Dr. Christian Heidbreder will advise the CEO on special projects through the end of 2026, and his employment will end December 31, 2026 as a termination without cause. At the May 13, 2026 annual meeting, shareholders elected all eight director nominees, approved executive pay on an advisory basis, and ratified PricewaterhouseCoopers LLP as auditor for 2026.
Chief Scientific Officer position eliminated effective June 1, 2026
Dr. Christian Heidbreder's employment terminates December 31, 2026, treated as termination without cause
All eight director nominees elected to one-year terms ending at the 2027 annual meeting
Say-on-pay approved with 90,364,566 votes for and 1,324,996 against; 91,848,954 votes favored annual say-on-pay votes
Indivior reported first-quarter 2026 total net revenue of $317 million, up 19% from a year earlier, and GAAP net income of $89 million, or $0.69 per diluted share, versus $47 million, or $0.38, in the prior-year quarter. The company raised its full-year 2026 net revenue and adjusted EBITDA guidance, and said it will not advance two pipeline drugs internally, which shifts the company's focus toward its SUBLOCADE treatment.
Q1 2026 SUBLOCADE net revenue was $232 million, up 32% year over year; total net revenue was $317 million, up 19%.
GAAP net income was $89 million ($0.69 diluted EPS) versus $47 million ($0.38) a year earlier; adjusted EBITDA was $164 million, up 112%.
2026 net revenue guidance was raised to $1,215 million to $1,285 million from $1,125 million to $1,195 million; adjusted EBITDA guidance was raised to $620 million to $660 million from $535 million to $575 million.
Indivior will not pursue Phase 3 development of INDV-6001, and INDV-2000 did not meet its Phase 2 primary endpoint; the company will seek external partners for INDV-2000.
Indivior Pharmaceuticals, Inc. issued $500 million of 0.625% convertible senior notes due March 15, 2031, including a $50 million option exercised in full, and used part of the proceeds to prepay and terminate its Note Purchase Agreement dated November 4, 2024. The filing names Indivior Pharmaceuticals, Inc. and ticker INDV, not Supernus, as the request stated; the details here follow the filing. Shareholders face potential dilution of up to 16,202,200 shares on conversion, and the notes add $500 million of senior unsecured debt.
$500 million principal of 0.625% Convertible Senior Notes due March 15, 2031, issued March 17, 2026
Initial conversion price of approximately $41.66 per share, a 35.0% premium over the March 12, 2026 closing price
Up to 16,202,200 common shares may be issued on conversion at the initial maximum conversion rate
Prepaid all outstanding principal, interest and fees under the Note Purchase Agreement; it terminated March 17, 2026
Indivior reported fourth-quarter 2025 net revenue of $358 million, up 20% from a year earlier, and GAAP net income of $102 million ($0.79 per diluted share) versus $21 million a year earlier. The company also authorized a new $400 million share repurchase program and reaffirmed its full-year 2026 guidance, including net revenue of $1,125 million to $1,195 million and adjusted EBITDA of $535 million to $575 million.
Q4 2025 total SUBLOCADE net revenue was $252 million, up 30% year over year; full-year SUBLOCADE net revenue was $856 million, up 13%.
FY 2025 GAAP net income was $210 million ($1.64 per diluted share), compared with $7 million in FY 2024.
New share repurchase program of up to $400 million with a term of up to 18 months, to be made opportunistically from available cash.
Cash and investments ended Q4 2025 at $222 million, down from $347 million a year earlier, after the $295 million legacy DOJ payment.
Indivior, which the filing identifies as Indivior Pharmaceuticals, Inc., completed its change of domicile to the United States after the close of trading on January 23, 2026, making Indivior U.S. a Delaware company and the parent of Indivior PLC. The filing also covers an amendment to a note purchase agreement, new indemnification agreements, a 2026 equity plan, and officer and director details, which show how the company is governed after the change. Shareholders receive one share of Indivior U.S. common stock for each Indivior PLC ordinary share they held.
The scheme of arrangement became effective after the close of trading on January 23, 2026, and each Indivior PLC ordinary share was cancelled in exchange for one share of Indivior U.S. common stock, par value $0.001.
A First Amendment to the Note Purchase Agreement, dated January 21, 2026 and effective January 26, 2026, moves financial reporting to Indivior U.S. from Indivior U.K.
The Indivior U.S. 2026 Omnibus Equity Incentive Plan reserves 17,500,000 shares, and non-employee director pay is capped at $1,000,000 per fiscal year.
Joe Ciaffoni is listed as Chief Executive Officer and Ryan Preblick as Chief Financial Officer.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Indivior filing is on SEC EDGAR ↗. 8-K briefs of other companies →